ALKEMAlkem Laboratories Limited
Pharma · Drug Manufacturers - Specialty & Generic · NSE · as of 2026-09-11 (delayed ~30 min in market hours)
Alkem Laboratories Limited, a pharmaceutical company, engages in the research and development, manufacture, and sale of pharmaceutical and nutraceutical products in India, the United States, and internationally. The company offers branded generics, generic drugs, active pharmaceutical ingredients, and biosimilars, and nutraceuticals in acute and chronic therapeutic areas comprising anti-infective, gastroenterology, pain management, iron deficiency, diabetology, central nervous system, anti-osteoporosis, gynecology, respiratory, ophthalmology, rheumatology, urology, dermatology, cardiology, neurology, and oncology. It also provides vitamins, minerals, and nutrients; cough syrups, hepatoprotective tonic, anti-dandruff shampoo, mouth wash, pregnancy detection kits, and condoms; and anti-bloating syrups, tablets, and powder. The company was incorporated in 1973 and is headquartered in Mumbai, India.
Price & Volume
Loading chart…
Key Ratios
“—” means the figure isn't meaningful or isn't published for this company: ROE and Debt/Equity are undefined when shareholder equity is negative (check P/B — negative means negative equity), and DII/MF holding splits aren't provided by our current data source.
Active Pattern Signals
None of the 16 pattern scanners currently detects a setup on ALKEM — signals appear here automatically when one forms (checked on every data refresh). The Trade Plan on the right always provides stop-loss and target levels regardless.
The picture
- • ROE: 17.6%
- • ROCE: 16.5%
- • Debt/Equity: 0.14
- • Trend strength (ADX): 34
- • Volume: 2.0x 20-day average
- • Distance from 52-week high: 13.6% below high
Bull case
- • ROE: 17.6%
- • ROCE: 16.5%
- • Debt/Equity: 0.14
- • Trend strength (ADX): 34
Bear case
- • Profit growth: -22.7% YoY
- • RSI: 29
- • MACD: bearish
- • 1-month return: -6.6%
Key risks
- • Momentum is fading versus the broader market
- • Profit growth: -22.7% YoY
- • RSI: 29
Algorithmic analysis for research only — not SEBI-registered investment advice.
Trade Plan
Stop = 20-day support with a 2.5×ATR risk cap (ATR ₹101.69). Levels recompute on every data refresh. Position sizing and execution are yours — this is analysis, not advice.